Biogen (BIIB) Cash from Financing Activities (2009 - 2026)

Biogen (BIIB) has reported Cash from Financing Activities for 18 consecutive years, with -$43.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 90.43% year-over-year to -$43.8 million; the TTM figure through Mar 2026 stood at -$322.7 million (down 20.91% YoY), while the FY2025 annual figure was -$301.9 million, up 55.83% from the prior year.
• Cash from Financing Activities came in at -$43.8 million for Q1 2026 at Biogen, up from -$137.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $848.6 million in Q3 2023, with the low at -$1.3 billion in Q3 2022.
• Average Cash from Financing Activities over 5 years is -$154.5 million, with a median of -$43.4 million recorded in 2023.
• The largest YoY upside for Cash from Financing Activities was 167.78% in 2023 against a maximum downside of 8631.08% in 2023.
• Year by year, Cash from Financing Activities stood at -$7.4 million in 2022, then slumped by 8631.08% to -$646.1 million in 2023, then soared by 101.22% to $7.9 million in 2024, then slumped by 1834.18% to -$137.0 million in 2025, then jumped by 68.03% to -$43.8 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$43.8 million, -$137.0 million, and -$130.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.